ERBB2 and breast cancer: Three CDK4/6 inhibitors, namely palbociclib, abemaciclib, and ribociclib, are currently approved as treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced BC in combination with endocrine therapy (ET) [5].